stiinte med 3 2011.indd - Academia de Ştiinţe a Moldovei

272
ACI (European Academy of Allergology and Clinical
Immunology) şi ARIA (Allergic Rhinitis and its Impact
on Asthma) 2008 referitor la eficacitatea clinică
în tratamentul RA.
Buletinul AŞM
Bibliografie selectivă
1. Anatomical Therapeutic Chemical (ATC) classifi -
cation index with Defi ned Daily Doses (DDD’s). WHO collaborating
Centre for Drug Statistics Methodology, Oslo,
Norway. January, 2004.
2. Bachert C. Decongestant effi cacy of Laevocetirizine
in patients with seasonal allergic rhinitis. In: Allergy,
2001, 56 (suppl. 65), p. 14-30.
3. Desager J.P., Horsmans Y. Pharmacokineticpharmacodynamic
relationships of H1-antihistamines. In:
Clin. Pharmacokinet, 1995, 28, p. 419-432.
4. Du Buske L.M. Clinical compasion of histamine
H1-receptor antagonist drugs. In: J. Allergy Clin. Immunol.,
1996, 98(6 Pt 3), p. S30 7-318.
5. Finn A.F. Jr., Kaplan A.P., Fretwell R., Qu R., Long
J. A double-blind, placebo-controlled trial of fexofenadine
HCl in the treatment of chronic idiopathic urticaria. In: J.
Allergy Clin., Immunol., 1999, 104(5), p. 1071-1078.
6. Horak F., Stubner U., Zieglmayer R. et al. Onset
and duration of action of desloratadine. XIX Congress of
Europ. Academy of Allergology and Clinical Immunology,
Lisbon, 2000.
7. Marone G. Milestones in the biology and pharmacology
of H1-receptor antagonists. In: Allergy, 1997,
52(34 Suppl), p. 7-13.
8. Nelson H., Reynolds R., Mason J. Fexofenadine
HCl is safe and effective for treatment of chronic idiopathic
urticaria. In: Ann. Allergy Asthma Immunol., 2000,
84(5), p. 517-522.
9. Noman P., Dimmann A., Laevocetirizin: a preclinical
and clinical overview. In: Drugs Today, 201, 37(4),
p. 215-227.
10. Ormerod A.D. Urticaria: recognition, causes and
treatment. In: Drugs, 1994, 48, p. 717-730.
11. Ring J., Hein R., Gauger A. Desloratadine in the
treatment of chronic idiopathic urticaria. In: Allergy, 2001,
56 (suppl. 65), p. 28-32.
12. Simons F.E., Murray H.E., Simons K.J. Quantitation
of H1-receptor anatagonists in skin and serum. In: J.
Allergy Clin. Immunol., 1995, 95, p. 759-764.
13. Simons F.E., Simons K.J. Clinical pharacology of
new histamine H1-receptor antagonists. In: Clin. Pharmacokinet,
1999, 36(5), p. 329-352.
Rezumat
A fost studiat efectul preparatului xyzal în calitate de
terapie de bază în rinita alergică. Administrarea preparatului
xyzal a demonstrat o activitate antihistaminică calitativă,
eficacitate clinică înaltă, ce asigură controlul asupra
simptomelor inflamaţiei alergice, comparativ cu alte antihistaminice,
aceste proprietăţi fiind determinate de particularităţile
sale farmacologice.
Summary
There have been studied the efficacy of Xyzal drug
as basic treatment in allergic rhinitis. Administration of
Xyzal demonstrated antihistaminic qualitative activity,
good clinical efficiency which assured the control of
allergic inflammation symptoms, compared with other
antihistamines, being determined by its pharmacologic
particularities.
Резюме
Были изучены эффективность, актуальность и безопасность
применения нового антигистаминного препарата
3-го поколения xyzal в лечении аллергических
ринитов по сравнению с препаратами предыдущих 1-й
и 2-й поколений.